Melatonin and brain inflammaging

Progress in Neurobiology

Volumn 127-128, Issue , 2015, Pages 46-63

  Hardeland, Rüdiger ^a   Cardinali, Daniel P ^b   Brown, Gregory M ^c   Pandi Perumal, Seithikurippu R ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aging; Alzheimer's disease; Circadian; Mitochondria; Neuroinflammation; Neuroprotection

Indexed keywords

MELATONIN;

AGING; ANIMAL; BRAIN; DEGENERATIVE DISEASE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSENESCENCE; METABOLISM; PHYSIOLOGY;

AGING; ANIMALS; BRAIN; HUMANS; IMMUNOSENESCENCE; MELATONIN; NEURODEGENERATIVE DISEASES; NEUROIMMUNOMODULATION;

EID: 84936938729     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.02.001     Document Type: Review

References (314)

1. Acosta J.C., Banito A., Wuestefeld T., Georgilis A., Janich P., Morton J.P., Athineos D., Kang T.W., Lasitschka F., Andrulis M., Pascual G., Morris K.J., Khan S., Jin H., Dharmalingam G., Snijders A.P., Carroll A.P., Capper D., Pritchard C., Inman G.J., Longerich T., Sansom O.J., Benitah S.A., Zender L., Gil J. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 2013, 15:978-990.
2. Acuña-Castroviejo D., Escames G., León J., Carazo A., Khaldy H. Mitochondrial regulation by melatonin and its metabolites. Adv. Exp. Med. Biol. 2003, 527:549-557.
3. Acuña-Castroviejo D., Escames G., López L.C., Hitos A.B., León J. Melatonin and nitric oxide: two required antagonists for mitochondrial homeostasis. Endocrine 2005, 27:159-168.
4. Acuña-Castroviejo D., Escames G., Rodríguez M.I., López L.C. Melatonin role in the mitochondrial function. Front. Biosci. 2007, 12:947-963.
5. Adler A.S., Sinha S., Kawahara T.L., Zhang J.Y., Segal E., Chang H.Y. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev. 2007, 21:3244-3257.
6. Afanas'ev I. Signaling and damaging functions of free radicals in aging-free radical theory, hormesis, and TOR. Aging Dis. 2010, 1:75-88.
7. + cells in humans. Mech. Ageing Dev. 2006, 127:560-566.
8. Alvira D., Tajes M., Verdaguer E., Acuña-Castroviejo D., Folch J., Camins A., Pallas M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J. Pineal Res. 2006, 40:251-258.
9. Andrabi S.A., Sayeed I., Siemen D., Wolf G., Horn T.F. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J. 2004, 18:869-871.
10. 125I]-CLINDE in the quinolinic acid rat model of excitotoxicity: a longitudinal comparison with microglial activation, astrogliosis, and neuronal death. Mol. Imaging 2014, 13:4-11.
11. Ayar A., Martin D.J., Ozcan M., Kelestimur H. Melatonin inhibits high voltage activated calcium currents in cultured rat dorsal root ganglion neurones. Neurosci. Lett. 2001, 313:73-77.
12. Balduini W., Carloni S., Perrone S., Bertrando S., Tataranno M.L., Negro S., Proietti F., Longini M., Buonocore G. The use of melatonin in hypoxic-ischemic brain damage: an experimental study. J. Matern. Fetal Neonatal Med. 2012, 25(Suppl. 1):119-124.
13. Barjavel M.J., Mamdouh Z., Raghbate N., Bakouche O. Differential expression of the melatonin receptor in human monocytes. J. Immunol. 1998, 160:1191-1197.
14. Basova L.V., Kurnikov I.V., Wang L., Ritov V.B., Belikova N.A., Vlasova I.I., Pacheco A.A., Winnica D.E., Peterson J., Bayir H., Waldeck D.H., Kagan V.E. Cardiolipin switch in mitochondria: shutting off the reduction of cytochrome c and turning on the peroxidase activity. Biochemistry 2007, 46:3423-3434.
15. Bayir H., Tyurin V.A., Tyurina Y.Y., Viner R., Ritov V., Amoscato A.A., Zhao Q., Zhang Y.J., Janaesko-Feldman K.L., Alexander H., Basova L.V., Clark R.S., Kochanek P.M., Kagan V.E. Selective early cardiolipin peroxidation after traumatic brain injury: an oxidative lipidomics analysis. Ann. Neurol. 2007, 62:154-169.
16. Bender Hoppe J., Frozza R.L., Horn A.P., Argenta Comiran R., Bernardi A., Campos M.M., Oliveira Battastini A.M., Salbego C. Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3β, tau and neuroinflammation. J. Pineal Res. 2010, 48:230-238.
17. Blasko I., Marx F., Steiner E., Hartmann T., GrubeckLoebenstein B. TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J. 1999, 13:63-68.
18. Blasko I., Veerhuis R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P., Grubeck.Loebenstein B. Costimulatory effects of interferon-γ and interkeukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol. Dis. 2000, 7. 692-689.
19. Blaylock R.L. Immunology primer for neurosurgeons and neurologists. Part 2: Innate brain immunity. Surg. Neurol. Int. 2013, 4:118.
20. Boren E., Gershwin M.E. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun. Rev. 2004, 3:401-406.
21. Bossù P., Ciaramella A., Salani F., Vanni D., Palladino I., Caltagirone C., Scapigliati G. Interleukin-18, from neuroinflammation to Alzheimer's disease. Curr. Pharm. Des. 2010, 16:4213-4224.
22. Bowerman M., Vincent T., Scamps F., Perrin F.E., Camu W., Raoul C. Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Front. Cell. Neurosci. 2013, 7:214.
23. Brown G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Trans. 2007, 35(Pt. 5):1119-1121.
24. Brown G.C., Neher J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41:242-247.
25. Brown G.M., Young S.N., Gauthier S., Tsui H., Grota L.J. Melatonin in human cerebrospinal fluid in daytime; its origin and variation with age. Life Sci. 1979, 25:929-936.
26. -B cells in centenarian offspring and elderly people. Age (Dordr.) 2013, 35:2009-2024.
27. 2-formyl-5-methoxykynuramine, resveratrol and uric acid. Int. J. Biochem. Cell Biol. 2001, 33:775-783.
28. Campuzano O., Castillo-Ruiz M.M., Acarin L., Castellano B., Gonzalez B. Distinct pattern of microglial response, cyclooxygenase-2, and inducible nitric oxide synthase expression in the aged rat brain after excitotoxic damage. J. Neurosci. Res. 2008, 86:3170-3183.
29. Candore G., Colonna-Romano G., Balistreri C.R., Di Carlo D., Grimaldi M.P., Listi F., Nuzzo D., Vasto S., Lio D., Caruso C. Biology of longevity; role of the innate immune system. Rejuvenation Res. 2006, 9:143-148.
30. Candore G., Caruso C., Colonna-Romano G. Inflammation, genetic background and longevity. Biogerontology 2010, 11:565-573.
31. Cano Barquilla P., Pagano E.S., Jiménez-Ortega V., Fernández-Mateos P., Esqifino A.I., Cardinali D.P. Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. J. Pineal Res. 2014, 57:280-290.
32. Capri M., Monti D., Salvioli S., Lescai F., Altilia S., Sevini F., Valensin S., Ostan R., Bucci L., Franceschi C. Complexity of anti-immunosenescence strategies in humans. Artif. Organs 2006, 30:730-742.
33. Cardinali D.P., Esquifino A.I., Srinivasan V., Pandi-Perumal S.R. Melatonin and the immune system in aging. Neuroimmunomodulation 2008, 15:272-278.
34. Cardinali D.P., Pandi-Perumal S.R., Niles L.P. Melatonin and its receptors: biological function in circadian sleep-wake regulation. Neurochemistry of Sleep and Wakefulness 2008, 283-314. Cambridge University Press, Cambridge, UK. J.M. Monti, S.R. Pandi-Perumal, C.M. Sinton (Eds.).
35. Cardinali D.P., Furio A.M., Brusco L.I. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr. Neuropharmacol. 2010, 8:218-227.
36. Carretero M., Escames G., López L.C., Venegas C., Dayoub J.C., García L., Acuña-Castroviejo D. Long-term melatonin administration protects brain mitochondria from aging. J. Pineal Res. 2009, 47:192-200.
37. Carrillo-Vico A., García-Mauriño S., Calvo J.R., Guerrero J.M. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J. 2003, 17:755-757.
38. Carrillo-Vico A., Guerrero J.M., Lardone P.J., Reiter R.J. A review of the multiple actions of melatonin on the immune system. Endocrine 2005, 27:189-200.
39. Carrillo-Vico A., Reiter R.J., Lardone P.J., Herrera J.L., Fernández-Montesinos R., Guerrero J.M., Pozo D. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs 2006, 7:423-431.
40. Carrillo-Vico A., Lardone P.J., Álvarez-Sánchez N., Rodríguez-Rodríguez A., Guerrero J.M. Melatonin: buffering the immune system. Int. J. Mol. Sci. 2013, 14:8638-8683.
41. Cevenini E., Monti D., Franceschi C. Inflamm-aging. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16:14-20.
42. Chandra A., Johri A., Beal M.F. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov. Disord. 2014, 29:285-293.
43. Chang H.C., Guarente L. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 2013, 153:1448-1460.
44. Chang H.M., Wu U.I., Lan C.T. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J. Pineal Res. 2009, 47:211-220.
45. Chang C.F., Huang H.J., Lee H.C., Hung K.C., Wu R.T., Lin A.M. Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and α-synuclein aggregation. J. Pineal Res. 2012, 52:312-321.
46. Cheng S., Ma C., Qu H., Fan W., Pang J., He H. Differential effects of melatonin on hippocampal neurodegeneration in different aged accelerated senescence prone mouse-8. Neuro Endocrinol. Lett. 2008, 29:91-99.
47. Chiang R.P.-Y., Huang C.-T., Tsai Y.-J. Melatonin reduces median nerve injury-induced mechanical hypersensitivity via inhibition of microglial p38 mitogen-activated protein kinase activation in rat cuneate nucleus. J. Pineal Res. 2013, 54:232-244.
48. Choo X.Y., Alukaidey L., White A.R., Grubman A. Neuroinflammation and copper in Alzheimer's disease. Int. J. Alzheimers Dis. 2013, 2013:145345.
49. Chu C.T., Ji J., Dagda R.K., Jiang J.F., Tyurina Y.Y., Kapralov A.A., Tyurin V.A., Yanamala N., Shrivastava I.H., Mohammadyani D., Qiang Wang K.Z., Zhu J., Klein-Seetharaman J., Balasubramanian K., Amoscato A.A., Borisenko G., Huang Z., Gusdon A.M., Cheikhi A., Steer E.K., Wang R., Baty C., Watkins S., Bahar I., Bayir H., Kagan V.E. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 2013, 15:1197-1205.
50. Clapp-Lilly K.L., Smith M.A., Perry G., Duffy L.K. Melatonin reduces interleukin secretion in amyloid-β stressed mouse brain slices. Chem. Biol. Interact. 2001, 134:101-107.
51. Clark I.A., Vissel B. Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem. Pharmacol. 2013, 86:862-871.
52. Clément P., Gharib A., Cespuglio R., Sarda N. Changes in sleep-wake cycle architecture and cortical nitric oxide release during ageing in the rat. Neuroscience 2003, 116:863-870.
53. Colonna-Romano G., Buffa S., Bulati M., Candore G., Lio D., Pellicanò M., Vasto S., Caruso C. B cells compartment in centenarian offspring and old people. Curr. Pharm. Des. 2010, 16:604-608.
54. Coppé J.P., Patil C.K., Rodier F., Sun Y., Muñoz D.P., Goldstein J., Nelson P.S., Desprez P.Y., Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
55. Coppé J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5:99-118.
56. Corthell J.T., Olcese J., Trombley P.Q. Melatonin in the mammalian olfactory bulb. Neuroscience 2014, 261:74-84.
57. Cristofanon S., Uguccioni F., Cerella C., Radogna F., Dicato M., Ghibelli L., Diederich M. Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-κB activation. Ann. N.Y. Acad. Sci. 2009, 1171:472-478.
58. Cristòfol R., Porquet D., Corpas R., Coto-Montes A., Serret J., Camins A., Pallàs M., Sanfeliu C. Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. J. Pineal Res. 2012, 52:271-281.
59. Crotti A., Benner C., Kerman B.E., Gosselin D., Lagier-Tourenne C., Zuccato C., Cattaneo E., Gage F.H., Cleveland D.W., Glass C.K. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 2014, 17:513-521.
60. Cuesta S., Kireev R., Forman K., Garcia C., Escames G., Ariznavarreta C., Vara E., Tresguerres J.A.F. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Exp. Gerontol. 2010, 45:950-956.
61. Cuesta S., Kireev R., García C., Forman K., Escames G., Vara E., Tresguerres J.A.F. Beneficial effect of melatonin treatment on inflammation, apoptosis and oxidative stress on pancreas of a senescence accelerated mice model. Mech. Ageing Dev. 2011, 132:573-582.
62. Cuesta S., Kireev R., García C., Rancan L., Tresguerres J.A.F. Melatonin can improve insulin resistance and aging-induced alterations in senescence-accelerated prone male mice (SAMP8). Age (Dordr.) 2013, 35:659-671.
63. Dal Prà I., Chiarini A., Gui L., Chakravarthy B., Pacchiana R., Gardenal E., Whitfield J.F., Armato U. Do astrocytes collaborate with neurons in spreading the infectious Aβ and tau drivers of Alzheimer's disease?. Neuroscientist 2014, 10.1177/1073858414529828.
64. Davalos A.R., Coppé J.P., Campisi J., Desprez P.Y. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010, 29:273-283.
65. De Felice F.G., Lourenco M.V., Ferreira S.T. How does brain insulin resistance develop in Alzheimer's disease?. Alzheimers Dement. 2014, 10(Suppl. 1):S26-S32.
66. De la Fuente M., Miquel J. An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflamm-aging. Curr. Pharm. Des. 2009, 15:3003-3026.
67. de la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem. Pharmacol. 2014, 88:548-559.
68. de la Rocha N.E., Rotelli A.E., Guardia T., Pelzer L.E. Different effects of melatonin on experimental granulomatous inflammation. Inflammation 2004, 28:189-193.
69. DelaRosa O., Pawelec G., Peralbo R., Wikby A., Mariani E., Mocchegiani E., Tarazona R., Solana R. Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology 2006, 7:471-481.
70. Deng W.G., Tang S.T., Tseng H.P., Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108:518-524.
71. Deng Y.Q., Xu G.G., Duan P., Zhang Q., Wang J.Z. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol. Sin. 2005, 26:519-526.
72. de Rivero Vaccari J.P., Dietrich W.D., Keane R.W. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J. Cereb. Blood Flow Metab. 2014, 34:369-375.
73. Dewan S.K., Zheng S.B., Xia S.J., Bill K. Senescent remodeling of the immune system and its contribution to the predisposition of the elderly to infections. Chin. Med. J. (Engl.) 2012, 125:3325-3331.
74. Dragicevic N., Copes N., O'Neill-Moffitt G., Jin J., Buzzeo R., Mamcarz M., Tan J., Cao C., Olcese J.M., Arendash G.W., Bradshaw P.C. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res. 2011, 51:75-86.
75. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm. 2006, 113:1685-1695.
76. Entrena A., Camacho M.E., Carrión M.D., López-Cara L.C., Velasco G., León J., Escames G., Acuña-Castroviejo D., Tapias V., Gallo M.A., Vivo A., Espinosa A. Kynurenamines as neural nitric oxide synthase inhibitors. J. Med. Chem. 2005, 48:8174-8181.
77. Escames G., López L.C., Ortíz F., Ros E., Acuña-Castroviejo D. Age-dependent lipopolysaccharide-induced iNOS expression and multiorgan failure in rats: effects of melatonin treatment. Exp. Gerontol. 2006, 41:1165-1173.
78. Escames G., López L.C., Tapias V., Utrilla P., Reiter R.J., Hitos A.B., León J., Rodríguez M.I., Acuña-Castroviejo D. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J. Pineal Res. 2006, 40:71-78.
79. Escames G., López L.C., Ortíz F., López A., García J.A., Ros E., Acuña-Castroviejo D. Attenuation of cardiac mitochondrial dysfunction by melatonin in septic mice. FEBS J. 2007, 274:2135-2147.
80. Esposito E., Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol. 2010, 8:228-242.
81. Fariello R.G., Bubenik G.A., Brown G.M., Grota L.J. Epileptogenic action of intraventricularly injected antimelatonin antibody. Neurology 1977, 27:567-570.
82. Feng Y.-M., Jia Y.-F., Su L.-Y., Wang D., Lv L., Xu L., Yao Y.G. Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin. Autophagy 2013, 9:18-29.
83. Feng Z., Qin C., Chang Y., Zhang J.T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 2006, 40:101-109.
84. Fenoglio-Simeone K., Mazarati A., Sefidvash-Hockley S., Shin D., Wilke J., Milligan H., Sankar R., Rho J.M., Maganti R. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav. 2009, 16:52-57.
85. Ferreira S.T., Clarke J.R., Bomfim T.R., De Felice F.G. Inflammation, defective insulin signaling, and neurological dysfunction in Alzheimer's disease. Alzheimers Dement. 2014, 10(Suppl. 1):S76-S83.
86. Forman K., Vara E., García C., Kireev R., Cuesta S., Acuña-Castroviejo D., Tresguerres J.A.F. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J. Pineal Res. 2010, 49:312-320.
87. Forman K., Vara E., García C., Kireev R., Cuesta S., Escames G., Tresguerres J.A.F. Effects of combined treatment with growth hormone and melatonin in the cardiological aging on male SAMP8 mice. J. Gerontol. A. Biol. Sci. Med. Sci. 2011, 66:823-834.
88. Franceschi C., Bonafè M. Centenarians as a model for healthy aging. Biochem. Soc. Trans. 2003, 31:457-461.
89. Franceschi C., Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A. Biol. Sci. Med. Sci. 2014, 69:S4-S9.
90. Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Inflamm-aging. An evolutionary perspective in immunosenescence. Ann. N.Y. Acad. Sci. 2000, 908:244-254.
91. Freund A., Patil C.K., Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 2011, 30:1536-1548.
92. Fumagalli M., d'Adda di Fagagna F. SASPense and DDRama in cancer and ageing. Nat. Cell Biol. 2009, 11:921-923.
93. Fuster-Matanzo A., Llorens-Martín M., Hernández F., Avila J. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm. 2013, 2013:260925.
94. García J.J., Piñol-Ripoll G., Martínez-Ballarín E., Fuentes-Broto L., Miana-Mena F.J., Venegas C., Caballero Escames G., Coto-Montes A., Acuña-Castroviejo D. Melatonin reduces membrane rigidity and oxidative damage in the brain of SAMP8 mice. Neurobiol. Aging 2011, 32:2045-2054.
95. + cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 1997, 159:574-581.
96. García-Mauriño S., González-Haba M.G., Calvo J.R., Goberna R., Guerrero J.M. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J. Neuroimmunol. 1998, 92:76-84.
97. García-Mauriño S., Pozo D., Carrillo-Vico A., Calvo J.R., Guerrero J.M. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci. 1999, 65:2143-2150.
98. García-Mesa Y., Giménez-Llort L., López L.C., Venegas C., Cristòfol R., Escames G., Acuña-Castroviejo D., Sanfeliu C. Melatonin plus physical exercise are highly neuroprotective in the 3×Tg-AD mouse. Neurobiol. Aging 2012, 33. 1124.e13-1124.e29.
99. Gayoso I., Sanchez-Correa B., Campos C., Alonso C., Pera A., Casado J.G., Morgado S., Tarazona R., Solana R. Immunosenescence of human natural killer cells. J. Innate Immun. 2011, 3:337-343.
100. Gilthorpe J.D., Oozeer F., Nash J., Calvo M., Bennett D.L., Lumsden A., Pini A. Extracellular histone H1 is neurotoxic and drives a pro-inflammatory response in microglia. F1000Res 2013, 2:148.
101. Giunta B., Fernandez F., Nikolic W.V., Obregon D., Rrapo E., Town T., Tan J. Inflammaging as a prodrome to Alzheimer's disease. J. Neuroinflammation 2008, 5:51.
102. Golombek D.A., Escolar E., Burin L.J., De Brito Sánchez M.G., Cardinali D.P. Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur. J. Pharmacol. 1991, 194:25-30.
103. Golombek D.A., Escolar E., Cardinali D.P. Melatonin-induced depression of locomotor activity in hamsters: time dependency and inhibition by the central type benzodiazepine antagonist Ro 15-1788. Physiol. Behav. 1991, 49:1091-1098.
104. Golombek D.A., Escolar E., Burin L.J., De Brito Sánchez M.G., Fernández Duque D., Cardinali D.P. Chronopharmacology of melatonin: inhibition by benzodiazepine antagonism. Chronobiol. Int. 1992, 9:124-131.
105. Golombek D.A., Fernández Duque D., De Brito Sánchez M.G., Burin L., Cardinali D.P. Time-dependent anticonvulsant activity of melatonin in hamsters. Eur. J. Pharmacol. 1992, 210:253-258.
106. Golombek D.A., Martíni M., Cardinali D.P. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur. J. Pharmacol. 1993, 237:231-236.
107. Golombek D.A., Pévet P., Cardinali D.P. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci. Biobehav. Rev. 1996, 20:403-412.
108. Gomez-Cabrera M.C., Sanchis-Gomar F., Garcia-Valles R., Pareja-Galeano H., Gambini J., Borras C., Viña J. Mitochondria as sources and targets of damage in cellular aging. Clin. Chem. Lab. Med. 2012, 50:1287-1295.
109. Goronzy J.J., Li G., Yang Z., Weyand C.M. The Janus head of T cell aging - autoimmunity and immunodeficiency. Front. Immunol. 2013, 4:131.
110. Grimaldi B., Nakahata Y., Kaluzova M., Masubuchi S., Sassone-Corsi P. Chromatin remodeling, metabolism and circadian clocks: the interplay of CLOCK and SIRT1. Int. J. Biochem. Cell Biol. 2009, 41:81-86.
111. Gruber J., Schaffer S., Halliwell B. The mitochondrial free radical theory of aging-where do we stand?. Front. Biosci. 2008, 13:6554-6579.
112. 1-acetyl-5-methoxykynuramine) with reactive nitrogen species: formation of novel compounds, 3-acetamidomethyl-6-methoxycinnolinone and 3-nitro-AMK. J. Pineal Res. 2005, 39:251-260.
113. Guerrero J.M., Reiter R.J. Melatonin-immune system relationships. Curr. Top. Med. Chem. 2002, 2:167-179.
114. Gunasingh M.J., Philip J.E., Ashok B.S., Kirubagaran R., Jebaraj W.C., Davis G.D., Vignesh S., Dhandayuthapani S., Jayakumar R. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogeneic amine catabolism. Life Sci. 2008, 83:96-102.
115. Gutierrez-Cuesta J., Sureda F.X., Romeu M., Canudas A.M., Caballero B., Coto-Montes A., Camins A., Pallàs M. Chronic administration of melatonin reduced cerebral injury biomarkers in SAMP8. J. Pineal Res. 2007, 42:394-402.
116. Hanzel C.E., Pichet-Binette A., Pomentel L.S., Iulita M.F., Allard S., Ducatenzeiler A., Do Carmo S., Cuello A.C. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol. Aging 2014, 35:2249-2262.
117. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005, 27:119-130.
118. Hardeland R. Melatonin, mitochondrial electron flux and leakage: recent findings and resolution of contradictory results. Adv. Stud. Biol. 2009, 1:207-230.
119. Hardeland R. Neuroprotection by radical avoidance: search for suitable agents. Molecules 2009, 14:5054-5102.
120. Hardeland R. Melatonin metabolism in the central nervous system. Curr. Neuropharmacol. 2010, 8:168-181.
121. Hardeland R. Cognitive enhancers in moderate to severe Alzheimer's disease. Clin. Med. Insights Ther. 2011, 3:459-476.
122. Hardeland R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J. Exp. Integr. Med. 2011, 1:67-81.
123. Hardeland R. Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012, 3:194-225.
124. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. J. Pineal Res. 2013, 55:325-356.
125. Hardeland R. Chronobiology of melatonin beyond the feedback to the suprachiasmatic nucleus - consequences to melatonin dysfunction. Int. J. Mol. Sci. 2013, 14:5817-5841.
126. Hardeland R., Coto-Montes A. New vistas on oxidative damage and aging. Open Biol. J. 2010, 3:39-52.
127. Hardeland R., Coto-Montes A., Poeggeler B. Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol. Int. 2003, 20:921-962.
128. Hardeland R., Ressmeyer A.-R., Zelosko V., Burkhardt S., Poeggeler B. Metabolites of melatonin: formation and properties of the methoxylated kynuramines AFMK and AMK. Recent Advances in Endocrinology and Reproduction: Evolutionary, Biotechnological and Clinical Applications 2004, 21-38. Banaras Hindu University, Varanasi. C. Haldar, S.S. Singh (Eds.).
129. 1-acetyl-5-methoxykynuramine. J. Pineal Res. 2007, 43:382-388.
130. Hardeland R., Poeggeler B., Pappolla M.A. Mitochondrial actions of melatonin-an endeavor to identify their adaptive and cytoprotective mechanisms. Abh. Sächs. Akad. Wiss. Math.-Nat. Kl. 2009, 65(Pt.3):14-31.
131. Hardeland R., Tan D.-X., Reiter R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009, 47:109-126.
132. Hardeland R., Cardinali D.P., Srinivasan V., Spence D.W., Brown G.M., Pandi-Perumal S.R. Melatonin - a pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93:350-384.
133. Hardeland R., Madrid J.A., Tan D.-X., Reiter R.J. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J. Pineal Res. 2012, 52:139-166.
134. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11:298-300.
135. Harman D. The biologic clock: the mitochondria?. J. Am. Geriatr. Soc. 1972, 20:145-147.
136. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann. N.Y. Acad. Sci. 2006, 1067:10-21.
137. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 1998, 18:8126-8132.
138. Herskovits A.Z., Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron 2014, 81:471-483.
139. Hirata F., Hayaishi O., Tokuyama T., Senoh S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem. 1974, 249:1311-1313.
140. Hirota T., Lewis W.G., Liu A.C., Lee J.W., Schultz P.G., Kay S.A. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20746-204751.
141. Hurd M.W., Ralph M.R. The significance of circadian organization for longevity in the golden hamster. J. Biol. Rhythms 1998, 13:430-436.
142. Hwang J.W., Yao H., Caito S., Sundar I.K., Rahman I. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic. Biol. Med. 2013, 61C:95-110.
143. Imai S. Clocks in the NAD world: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim. Biophys. Acta 2010, 1804:1584-1590.
144. + and sirtuins in aging and disease. Trends Cell Biol. 2014, 24:464-471.
145. Iñarrea P., Casanova A., Alava M.A., Iturralde M., Cadenas E. Melatonin and steroid hormones activate Cu,Zn-superoxide dismutase by means of mitochondrial cytochrome P450. Free Radic. Biol. Med. 2011, 50:1575-1581.
146. Ji M., Zhao W.J., Dong L.D., Miao Y., Yang X.L., Sun Y.H., Wang Z. RGS2 and RGS4 modulate melatonin-induced potentiation of glycine currents in rat retinal ganglion cells. Brain Res. 2011, 1411:1-8.
147. Jiménez-Ortega V., Cano P., Cardinali D.P., Esquifino A.I. 24-Hour variation in gene expression of redox pathway enzymes in rat hypothalamus: effect of melatonin treatment. Redox Rep. 2009, 14:132-138.
148. Jiang T., Yu J.T., Zhu X.C., Tan L. TREM2 in Alzheimer's disease. Mol. Neurobiol. 2013, 48:180-185.
149. 2+ stress in astrocyte. J. Pineal Res. 2011, 50:427-435.
150. Jou M.-J., Peng T.-I., Reiter R.J., Jou S.-B., Wu H.-Y., Wen S.-T. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal Res. 2004, 37:55-70.
151. Jun Z., Li Z., Fang W., Fengzhen Y., Puyuan W., Wenwen L., Zhi S., Bondy S.C. Mleatonin decreases levels of S100β and NFKB, increases levels of synaptophysin in a rat model of Alzheimer's disease. Curr. Aging Sci. 2013, 6:142-149.
152. Kagan V.E. Emerging free radical optimism: translational oxidative lipidomics. Eur. J. Clin. Invest. 2013, 43(Suppl. 1):57.
153. Kagan V.E., Bayir A., Bayir H., Stoyanovsky D., Borisenko G.G., Tyurina Y.Y., Wipf P., Atkinson J., Greenberger J.S., Chapkin R.S., Belikova N.A. Mitochondria-targeted disruptors and inhibitors of cytochrome c/cardiolipin peroxidase complexes: a new strategy in anti-apoptotic drug discovery. Mol. Nutr. Food Res. 2009, 53:104-114.
154. Kagan V.E., Bayir H.A., Belikova N.A., Kapralov O., Tyurina Y.Y., Tyurin V.A., Jiang J., Stoyanovski D.A., Wipf P., Kochanek P.M., Greenberger J.S., Pitt B., Shvedova A.A., Borisenko G. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic. Biol. Med. 2009, 46:1439-1453.
155. Kang D., Hamasaki N. Mitochondrial transcription factor A in the maintenance of mitochondrial DNA. Overview of its multiple roles. Ann. N.Y. Acad. Sci. 2005, 1042:101-108.
156. Karasek M., Reiter R.J. Melatonin and aging. Neuroendocrinol. Lett. 2002, 23(Suppl. 1):14-16.
157. Kelly R.W., Amato F., Seamark R.F. N-acetyl-5-methoxy kynurenamine, a brain metabolite of melatonin, is a potent inhibitor of prostaglandin biosynthesis. Biochem. Biophys. Res. Commun. 1984, 121:372-379.
158. Kienhöfer J., Häussler D.J., Ruckelshausen F., Muessig E., Weber K., Pomentel D., Ulrich V., Bürkle A., Bachschmid M.M. Association of mitochondrial antioxidant enzymes with mitochondrial DNA as integral nucleoid constituents. FASEB J. 2009, 23:2034-2044.
159. Kinoshita C., Miyazaki K., Ishida N. Chronic stress affects PERIOD2 expression through glycogen synthase kinase-3β phosphorylation in the central clock. Neuroreport 2012, 23:98-102.
160. Kireev R.A., Tresguerres A.C., Garcia C., Arriznavarreta C., Vara E., Tresguerres J.A.F. Melatonin is able to prevent the liver of old castrated female rats from oxidative and pro-inflammatory damage. J. Pineal Res. 2008, 45:394-402.
161. Kireev R.A., Vara E., Viña J., Tresguerres J.A.F. Melatonin and oestrogen treatments were able to improve neuroinflammation and apoptotic processes in dentate gyrus of old ovariectomized female rats. Age (Dordr.) 2014, 36:9707.
162. Korkmaz A., Topal T., Tan D.-X., Reiter R.J. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord. 2009, 10:261-270.
163. Korkmaz A., Rosales-Corral S., Reiter R.J. Gene regulation by melatonin linked to epigenetic phenomena. Gene 2012, 503:1-11.
164. Kozikowski A.P., Gunosewoyo H., Guo S., Gaisina I.N., Walter R.L., Ketcherside A., McClung C.A., Mesecar A.D., Caldarone B. Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivtiy in CLOCK mutant mice. ChemMedChem 2011, 6:1593-1602.
165. Kühlwein E., Irwin M. Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J. Neuroimmunol. 2001, 117:51-57.
166. Lahiri D.K. Melatonin affects the metabolism of the β-amyloid precursor protein in different cell types. J. Pineal Res. 1999, 26:137-146.
167. Lardone P.J., Carrillo-Vico A., Naranjo M.C., De Felipe B., Vallejo A., Karasek M., Guerrero J.M. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J. Cell. Physiol. 2006, 206:273-279.
168. Lee M.-Y., Kuan Y-H., Chen H.-Y., Chen T.-Y., Chen S.-T., Huang C.-C., Yang I.-P., Hsu Y.-S., Wu T.-S., Lee E.-J. Intravenous administration of melatonin reduced the intracerebral inflammatory response following transient focal cerebral ischemia in rats. J. Pineal Res. 2007, 42:297-309.
169. León J., Macías M., Escames G., Camacho E., Khaldy H., Martín M., Espinosa A., Gallo M.A., Acuña-Castroviejo D. Structure-related inhibition of calmodulin-dependent neuronal nitric-oxide synthase activity by melatonin and synthetic kynurenines. Mol. Pharmacol. 2000, 58:967-975.
170. León J., Escames G., Rodríguez M.I., López L.C., Tapias V., Entrena A., Camacho E., Carrión M.D., Gallo M.A., Espinosa A., Tan D.-X., Reiter R.J., Acuña-Castroviejo D. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J. Neurochem. 2006, 98:2023-2033.
171. Li X.C., Wang Z.F., Zhang J.X., Wang Q., Wang J.Z. Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur. J. Pharmacol. 2005, 510:25-30.
172. Liang H., Ran Q., Jang Y.C., Holstein D., Lechleiter J., McDonald-Marsh T., Musatov A., Song W., Van Remmen H., Richardson A. Glutathione peroxidase 4 differentially regulates the release of apoptogenic proteins from mitochondria. Free Radic. Biol. Med. 2009, 47:312-320.
173. Lin L., Huang Q.X., Yang S.S., Chu J., Wang J.Z., Tian Q. Melatonin in Alzheimer's disease. Int. J. Mol. Sci. 2013, 14:14575-45931.
174. Lin T.Y., Huang W.J., Wu C.C., Lu C.W., Wang S.J. Acacetin inhibits glutamate release and prevents kainic-acid-induced neurotoxicity in rats. PLOS ONE 2014, 9:e88644.
175. Linton P., Thoman M.L. T cell senescence. Front. Biosci. 2001, 6:D248-D261.
176. Lissoni P., Pittalis S., Rovelli F., Roselli M., Ardizzoia A. Modulation of cytokine production from TH2-lymphocytes and monocytes by the pineal neurohormone melatonin. Oncol. Rep. 1996, 3:541-543.
177. Listi F., Candore G., Modica M.A., Russo M., Di Lorenzo G., Esposito-Pelliteri M., Colonna-Romano G., Aquino A., Bulati M., Lio D., Franceschi C., Caruso C. A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann. N.Y. Acad. Sci. 2006, 1089:487-495.
178. Liu L., Chan C. The role of the inflammasome in Alzheimer's disease. Ageing Res. Rev. 2014, 15C:6-15.
179. Liu R.Y., Zhou J.N., van Heerikhuize J., Hofman M.A., Swaab D.F. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-e{open}4/4 genotype. J. Clin. Endocrinol. Metab. 1999, 84:323-327.
180. + current mediates the migration of rat cerebellar granule cells stimulated by melatonin. J. Neurochem. 2007, 102:333-344.
181. Lopategui Cabezas I., Herrera Batista A., Pentón Rol G. The role of glial cells in Alzheimer disease: potential therapeutic implications. Neurologia 2014, 29:305-309.
182. López L.C., Escames G., Tapias V., Utrilla P., León J., Acuña-Castroviejo D. Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: its relation with mitochondrial dysfunction and prevention by melatonin. Int. J. Biochem. Cell Biol. 2006, 38:267-278.
183. López A., García J.A., Escames G., Venegas C., Ortíz F., López L.C., Acuña-Castroviejo D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J. Pineal Res. 2009, 46:188-198.
184. Lu C., Schoenfeld R., Shan Y., Tsai H.J., Hammock B., Cortopassi G. Frataxin deficiency induces Schwann cell inflammation and death. Biochim. Biophys. Acta 2009, 1792:1052-1061.
185. Luchetti F., Canonico B., Mannello F., Masoni C., D'Emilio A., Battistelli M., Papa S., Falcieri E. Melatonin reduces early changes in intramitochondrial cardiolipin during apoptosis in U937 cell line. Toxicol. In Vitro 2007, 21:293-301.
186. Lyman M., Lloyd D.G., Ji X., Vizcaychipi M.P., Ma D. Neuroinflammation: the role and consequences. Neurosci. Res. 2014, 79:1-12.
187. Lynch M.A. The impact of neuroimmune changes on development of amyloid pathology: relevance to Alzheimer's disease. Immunology 2014, 141:292-301.
188. Manda K., Ueno M., Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J. Pineal Res. 2007, 42:386-393.
189. Manda K., Ueno M., Anzai K. Space radiation-induced inhibition of neurogenesis in the hippocampal dentate gyrus and memory impairment in mice: ameliorative potential of the melatonin metabolite, AFMK. J. Pineal Res. 2008, 45:430-438.
190. Marcheva B., Ramsey K.M., Buhr E.D., Kobayashi Y., Su H., Ko C.H., Ivanova G., Omura C., Mo S., Vitaterna M.H., Lopez J.P., Philipson L.H., Bradfield C.A., Crosby S.D., JeBailey L., Wang X., Takahashi J.S., Bass J. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 2010, 466:627-631.
191. Masilamoni J.G., Jesudason E.P., Dhandayuthapani S., Ashok B.S., Vignesh S., Jebaraj W.C., Paul S.F., Jayakumar S. The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radic. Res. 2008, 42:661-673.
192. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.-J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 2003, 85:1101-1108.
193. Mayo J.C., Sainz R.M., Tan D.-X., Antolín I., Rodríguez C., Reiter R.J. Melatonin and Parkinson's disease. Endocrine 2005, 27:169-178.
194. Mayo J.C., Sainz R.M., Tan D.-X., Hardeland R., León J., Rodriguez C., Reiter R.J. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol. 2005, 165:139-149.
195. McLarnon J.G. Correlated inflammatory responses and neurodegeneration in peptide-injected animal models of Alzheimer's disease. Biomed. Res. Int. 2014, 2014:923670.
196. Messner M., Hardeland R., Rodenbeck A., Huether G. Tissue retention and subcellular distribution of continuously infused melatonin in rats under near physiological conditions. J. Pineal Res. 1998, 25:251-259.
197. Michaud M., Balardy L., Moulis G., Gaudin C., Peyrot C., Vellas B., Cesari M., Nourhashemi F. Proinflammatory cytokines, aging, and age-related diseases. J. Am. Med. Dir. Assoc. 2013, 14:877-882.
198. Miller Z.A., Rankin K.P., Graff-Redford N.R., Takada L.T., Sturm V.E., Cleveland C.M., Criswell L.A., Jaeger P.A., Stan T., Heggeli K.A., Hsu S.C., Karydas A., Khan B.K., Grinberg L.T., Gomo-Tempini M.L., Boxer A.L., Rosen H.J., Kramer J.H., Coppola G., Geschwind D.H., Rademakers R., Seeley W.W., Wyss-Coray T., Miller B.L. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J. Neurol. Neurosurg. Psychiatry 2013, 84:956-962.
199. Min K.J., Jang J.H., Kwon T.K. Inhibitory effects of melatonin on the lipopolysaccharide-induced CC chemokine expression in BV2 murine microglial cells are mediated by suppression of Akt-induced NF-κB and STAT/GAS activity. J. Pineal Res. 2012, 52:296-304.
200. Miquel J., de Juan E., Sevila I. Oxygen-induced mitochondrial damage and aging. EXS 1992, 62:47-57.
201. Mocchegiani E., Giacconi R., Muti R., Cipriano C., Costarelli L., Tesei S., Gasparini N., Malavolta M. Zinc-bound metallothioneins and immune plasticity: lessons from very old mice and humans. Immun. Ageing 2007, 4:7.
202. Mocchegiani E., Giacconi R., Cipriano C., Malavolta M. NK and NKT cells in aging and longevity: role of zinc and metallothioneins. J. Clin. Immunol. 2009, 29:416-425.
203. Molina-Carballo A., Muñoz-Hoyos A., Sánchez-Forte M., Uberos-Fernández J., Moreno-Madrid F., Acuña-Castroviejo D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics 2007, 38:122-125.
204. Morales I., Guzmán-Martínet L., Cerda-Troncoso C., Farías G.A., Maccioni R.B. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell. Neurosci. 2014, 8:112.
205. More S.V., Kumar H., Kim I.S., Song S.Y., Choi D.K. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease. Mediators Inflamm. 2013, 2013:952375.
206. Morrey K.M., McLachlan J.A., Serkin C.D., Bakouche O. Activation of human monocytes by the pineal hormone melatonin. J. Immunol. 1994, 153:2671-2680.
207. Muñoz-Hoyos A., Sánchez-Forte M., Molina-Carballo A., Escames G., Martín-Medina E., Reiter R.J., Molina-Font J.A., Acuña-Castroviejo D. Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J. Child Neurol. 1998, 13:501-509.
208. +-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 2008, 134:329-340.
209. + salvage pathway by CLOCK-SIRT1. Science 2009, 324:654-657.
210. Narayan P., Holmström K.M., Kim D.H., Whitcomb D.J., Wilson M.R., St George-Hyslop P., Wood N.W., Dobson C.M., Cho K., Abramov A.Y., Kleneman D. Rare individual amyloid-β oligomers act on astrocytes to initiate neuronal damage. Biochemistry 2014, 53:2442-2453.
211. Negi G., Kumar A., Sharma S.S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy. Effects on NF-κB and Nrf2. J. Pineal Res. 2011, 50:124-131.
212. Niranjan R., Nath C., Shukla R. Melatonin attenuated mediators of neuroinflammation and α-7 nicotinic acetylcholine receptor mRNA expression in lipopolysaccharide (LPS) stimulated astrocytoma cells, C6. Free Radic. Res. 2012, 46:1167-1177.
213. Nishida S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine 2005, 27:131-136.
214. Nishida S., Segawa T., Murai I., Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J. Pineal Res. 2002, 32:26-33.
215. Nolan Y.M., Sullivan A.M., Toulouse A. Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol. Med. 2013, 19:187-196.
216. Nomaru H., Sakumi K., Katogi A., Ohnishi Y.N., Kajitani K., Tsuchimoto D., Nestler E.J., Nakabeppu Y. Fosb gene products contribute to excitotoxic microglial activation by regulating the expression of complement C5a receptors in microglia. Glia 2014, 62:1284-1298.
217. Nuzzo D., Picone P., Caruana L., Vasto S., Barera A., Caruso C., Di Carlo M. Inflammatory mediators as biomarkers in brain disorders. Inflammation 2014, 37:639-648.
218. O'Brien I.A., Lewin I.G., O'Hare J.P., Arendt J., Corrall R.J. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin. Endocrinol. (Oxf.) 1986, 24:359-364.
219. Olcese J.M., Cao C., Mori T., Mamcarz M.B., Maxwell A., Runfeldt M.J., Wang L., Zhang C., Lin X., Zhang G., Arendash G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administrations of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 2009, 47:82-96.
220. 2-formyl-5-methoxykynuramine, quercetin or resveratrol. J. Pineal Res. 2005, 38:107-115.
221. Ott M., Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922.
222. Öztürk G., Akbulut K.G., Güney S., Acuña-Castroviejo D. Age-related changes in the rat brain mitochondrial antioxidative enzyme ratios: modulation by melatonin. Exp. Gerontol. 2012, 47:706-711.
223. Pang C.S., Tsang S.F., Yang J.C. Effects of melatonin, morphine and diazepam on formalin-induced nociception in mice. Life Sci. 2001, 68:943-951.
224. Papp M., Litwa E., Gruca P., Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol. 2006, 17:9-18.
225. Pappolla M.A., Chyan Y., Poeggeler B., Frangione B., Wilson G., Ghiso J., Reiter R.J. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J. Neural Transm. 2000, 107:203-231.
226. Paradies G., Petrosillo G., Paradies V., Reiter R.J., Ruggiero F.M. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Res. 2010, 48:297-310.
227. + cycle drives mitochondrial oxidative metabolism in mice. Science 2013, 342:1243417.
228. Peng C.X., Hu J., Hong X.P., Wu Y.Y., Zhu L.Q., Wang J.Z. Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model. Neurobiol. Aging 2013, 34:1555-1563.
229. Permpoonputtana K., Govitrapong P. The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines. Neurotox. Res. 2013, 23:189-199.
230. Peschke E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 2008, 44:26-40.
231. Peschke E., Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24:829-841.
232. Peschke E., Stumpf I., Bazwinsky I., Litvak L., Dralle H., Mühlbauer E. Melatonin and type 2 diabetes - a possible link?. J. Pineal Res. 2007, 42:350-358.
233. Petrosillo G., Di Venosa N., Pistolese M., Casanova G., Tiravanti E., Colantuono G., Federici A., Paradies G., Ruggiero F.M. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin. FASEB J. 2006, 20:269-276.
234. Petrosillo G., Fattoretti P., Matera M., Ruggiero F.M., Bertoni-Freddari C., Paradies G. Melatonin prevents age-related mitochondrial dysfunction in rat brain via cardiolipin protection. Rejuvenation Res. 2008, 11:935-943.
235. Pfister G., Savino W. Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective. Neuroimmunomodulation 2008, 15:351-364.
236. Pinato L., da Silveira Cruz-Machado S., Franco D.G., Campos L.M.G., Cecon E., Fernandes P.A.C.M., Bittencourt J.C., Markus R.P. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct. Funct. 2013, 10.1007/s00429-013-0686-4.
237. Pinti M., Nasi M., Lugli E., Gibellini L., Bertoncelli L., Roat E., De Biasi S., Mussini C., Cossarizza A. T cell homeostasis in centenarians: from the thymus to the periphery. Curr. Pharm. Des. 2010, 16:597-603.
238. Poeggeler B. Melatonin, aging, and age-related diseases: perspectives for prevention, intervention, and therapy. Endocrine 2005, 27:201-212.
239. Ponnappan S., Ponnappan U. Aging and immune function: molecular mechanisms to interventions. Antioxid. Redox Signal. 2011, 14:1551-1585.
240. Prada C., Udin S.B. Melatonin decreases calcium levels in retinotectal axons of Xenopus laevis by indirect activation of group III metabotropic glutamate receptors. Brain Res. 2005, 1053:67-76.
241. C receptors. J. Neurophysiol. 2005, 94:968-978.
242. Quinn J., Kulhanek D., Nowlin J., Jones R., Praticò D., Rokach J., Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 2005, 1037:209-213.
243. Radogna F., Paternoster L., De Nicola M., Cerella C., Ammendola S., Bedini A., Tarzia G., Aquilano K., Ciriolo M., Ghibelli L. Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes. Toxicol. Appl. Pharmacol. 2009, 239:37-45.
244. Radogna F., Diederich M., Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem. Pharmacol. 2010, 80:1844-1852.
245. + biosynthesis. Science 2009, 324:651-654.
246. Rehan L., Laszki-Szczachor K., Sobieszańska M., Polak-Jonkisz D. SIRT1 and NAD as regulators of aging. Life Sci. 2014, 105:1-6.
247. Reiter R.J., Acuña-Castroviejo D., Tan D.-X., Burkhardt S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann. N.Y. Acad. Sci. 2001, 939:200-215.
248. Reiter R.J., Tan D.-X., Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech. Ageing Dev. 2002, 123:1007-1019.
249. Reiter R.J., Tan D.-X., Mayo J.C., Sainz R.M., Leon J., Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim. Pol. 2003, 50:1129-1146.
250. Rentzos M., Rombis A. The role of IL-15 in central nervous system disorders. Acta Neurol. Scand. 2012, 125:77-82.
251. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep. 2003, 8:205-213.
252. Ridolfi E., Barone C., Scarpini E., Galimberti D. The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. Clin. Dev. Immunol. 2013, 2013:939786.
253. Rizzo F., Riboldi G., Salani S., Nizzardo M., Simone C., Corti S., Hedlund E. Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2014, 71:999-1015.
254. Robeva R., Kirilov G., Tomova A., Kumanov P. Melatonin-insulin interactions in patients with metabolic syndrome. J. Pineal Res. 2008, 44:52-56.
255. Rodriguez G.A., Tai L.M., LaDu M.J., Rebeck G.W. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J. Neuroinflammation 2014, 11:111.
256. Rosales-Corral S.A., Acuña-Castroviejo D., Coto-Montes A., Boga J.A., Manchester L.C., Fuentes-Broto L., Korkmaz A., Ma S., Tan D.-X., Reiter R.J. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J. Pineal Res. 2012, 52:167-202.
257. Rosenstein R.E., Cardinali D.P. Central gabaergic mechanisms as target for melatonin activity. Neurochem. Int. 1990, 17:373-379.
258. Sack R.L., Lewy A.J., Erb D.L., Vollmer W.M., Singer C.M. Human melatonin production decreases with age. J. Pineal Res. 1986, 3:379-388.
259. Sahar S., Zocchi K., Kinoshita C., Borrelli E., Sassone-Corsi P. Regulation of BMAL1 protein stability and circadian function by GSK3β-mediated phosphorylation. PLoS ONE 2010, 5:e8561.
260. Salminen A., Ojala J., Kaamiranta K., Haapasalo A., Hiltunen M., Soininen H. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur. J. Neurosci. 2011, 34:3-11.
261. Salvioli S., Capri M., Valensin S., Tieri P., Monti D., Ottavani E., Franceschi C. Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr. Pharm. Des. 2006, 12:3161-3171.
262. Samhan-Arias A.K., Tyurina Y.Y., Kagan V.E. Lipid antioxidants: free radical scavenging versus regulation of enzymatic lipid peroxidation. J. Clin. Biochem. Nutr. 2011, 48:91-95.
263. Sansoni P., Vescovini R., Fagnoni F., Biasini C., Zanni L., Telera A., Lucchini G., Passeri G., Monti D., Franceschi C., Passeri M. The immune system in extreme longevity. Exp. Gerontol. 2008, 43:61-65.
264. Schlachetzki J.C., Hüll M. Microglial activation in Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:554-563.
265. Shafer L.L., McNulty.J.A., Young M.R. Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. J. Neuroimmunol. 2001, 120:84-93.
266. Shaw A.C., Joshi S., Greenwood H., Panda A., Lord J.M. Aging of the innate immune system. Curr. Opin. Immunol. 2010, 22:507-513.
267. Sheu S.S., Wang W., Cheng H., Dirksen R.T. Superoxide flashes: illuminating new insights into cardiac ischemia/reperfusion injury. Future Cardiol. 2008, 4:551-554.
268. Shieh J.-M., Wu H.-T., Cheng K.-C., Cheng J.-T. Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCζ-Akt-GSK3β pathway in hepatic cells. J. Pineal Res. 2009, 47:339-344.
269. Silva S.O., Rodrigues M.R., Ximenes V.F., Bueno-da-Silva A.E., Amarante-Mendes G.P., Campa A. Neutrophils as a specific target for melatonin and kynuramines: effects on cytokine release. J. Neuroimmunol. 2004, 156:146-152.
270. 2-formyl-5-methoxykynuramine, in cerebrospinal fluid of patients with meningitis: a possible immunomodulatory mechanism. J. Pineal Res. 2005, 39:302-306.
271. Skene D.J., Swaab D.F. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp. Gerontol. 2003, 38:199-206.
272. Skene D.J., Vivien-Roels B., Sparks D.L., Hunsaker J.C., Pévet P., Ravid D., Swaab D.F. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res. 1990, 528:170-174.
273. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 1997, 17:2653-2657.
274. Solmaz I., Gürkanlar D., Gökçil Z., Göksoy C., Ozkan M., Erdoğan E. Antiepileptic activity of melatonin in guinea pigs with pentylenetetrazol-induced seizures. Neurol. Res. 2009, 31:989-995.
275. Song W., Lahiri D.K. Melatonin alters the metabolism of the β-amyloid precursor protein in the neuroendocrine cell line PC12. J. Mol. Neurosci. 1997, 9:75-92.
276. Srinivasan V., Pandi-Perumal S.R., Maestroni G.J.M., Esquifino A.I., Hardeland R., Cardinali D.P. Role of melatonin in neurodegenerative diseases. Neurotox. Res. 2005, 7:293-318.
277. Srinivasan V., Pandi-Perumal S.R., Cardinali D.P., Poeggeler B., Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav. Brain Funct. 2006, 2:15.
278. Srinivasan V., Pandi-Perumal S.R., Spence D.W., Moscovitch A., Trakht I., Brown G.M., Cardinali D.P. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res. Bull. 2010, 81:362-371.
279. Srinivasan V., Cardinali D.P., Srinivasan U.S., Kaur C., Brown G.M., Spence D.W., Hardeland R., Pandi-Perumal S.R. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther. Adv. Neurol. Disord. 2011, 4:297-317.
280. Srinivasan V., Zakaria R., Jeet Singh H., Acuña-Castroviejo D. Melatonin and its agonists in pain modulation and its clinical application. Arch. Ital. Biol. 2012, 150:274-289.
281. Strindhall J., Nilsson B.O., Löfgren S., Ernerudh J., Pawelec G., Johansson B., Wikby A. No immune risk profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp. Gerontol. 2007, 42:753-761.
282. Sutinen E.M., Pirtillä T., Anderson G., Salminen A., Ojala J.O. Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cells. J. Neuroinflammation 2012, 9:199.
283. Szczepanik M. Melatonin and its influence on immune system. J. Physiol. Pharmacol. 2007, 58(Suppl. 6):115-124.
284. Tajes M., Gutierrez-Cuesta J., Ortuño-Sahagun D., Camins A., Pallàs M. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J. Pineal Res. 2009, 47:228-237.
285. Takeuchi H., Mizuno T., Zhang G., Wang J., Kawanokuchi J., Kuno R., Suzumura A. Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J. Biol. Chem. 2005, 280:10444-10454.
286. Tan D.-X., Manchester L.C., Burkhardt S., Sainz R.M., Mayo J.C., Kohen R., Shohami E., Huo Y.-S., Hardeland R., Reiter R.J. N1-Acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001, 15:2294-2296.
287. Tan D.-X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.
288. Tan B., Choi R.H., Chin T.J., Kaur C., Ling E.A. Manipulation of microglial activity as a therapy for Alzheimer's disease. Front. Biosci. 2012, 4:1402-1412.
289. 1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in Parkinsonian mice. J. Neurosci. Res. 2009, 87:3002-3010.
290. Taylor J.M., Main B.S., Crack P.J. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 2013, 62:803-819.
291. Thompson L.V. Oxidative stress, mitochondria and mtDNA-mutator mice. Exp. Gerontol. 2006, 41:1220-1222.
292. Tilleux S., Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J. Neurosci. Res. 2007, 85:2059-2070.
293. Tocharus J., Chongthammakun S., Govitrapong P. Melatonin inhibits amphetamine-induced nitric oxide synthase mRNA overexpression in microglial cell lines. Neurosci. Lett. 2008, 439:134-137.
294. Tocharus J., Khonthun C., Chongthammakun S., Govitrapong P. Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J. Pineal Res. 2010, 48:347-352.
295. Tricoire H., Locatelli A., Chemineau P., Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002, 143:84-90.
296. Tricoire H., Malpaux B., Møller M. Cellular lining of the sheep pineal recess studied by light-, transmission-, and scanning electron microscopy: morphologic indications for a direct secretion of melatonin from the pineal gland to the cerebrospinal fluid. J. Comp. Neurol. 2003, 456:39-47.
297. Tricoire H., Møller M., Chemineau P., Malpaux B. Origin of cerebrospinal fluid melatonin and possible function in the integration of photoperiod. Reprod. Suppl. 2003, 61:311-321.
298. Tyagi E., Agrawal R., Nath C., Shukla R. Effect of melatonin on neuroinflammation and acetylcholinesterase activity induced by LPS in rat brain. Eur. J. Pharmacol. 2010, 640:206-210.
299. Ulugol A., Dokmeci D., Guray G., Sapolyo N., Ozyigit F., Tamer M. Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: possible involvements of the l-arginine-NO pathway and opioid system. Life Sci. 2006, 78:1592-1597.
300. Urrutia P.J., Mena N.P., Núñez M.T. The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front. Pharmacol. 2014, 5:38.
301. Venegas C., García J.A., Escames G., Ortiz F., López A., Doerrier C., García-Corzo L., López L.C., Reiter R.J., Acuña-Castroviejo D. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J. Pineal Res. 2012, 52:217-227.
302. von Bernhardi R. Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox. Res. 2007, 12:215-232.
303. Wang W., Fang H., Groom L., Cheng A., Zhang W., Liu J., Wang X., Li K., Han P., Zheng M., Yin J., Wang W., Mattson M.P., Kao J.P., Lakatta E.G., Sheu S.S., Ouyang K., Chen J., Dirksen R.T., Cheng H. Superoxide flashes in single mitochondria. Cell 2008, 134:279-290.
304. Wang Y., Liu X., Wang W., Song W., Chen L., Fang Q., Yan X. The expression of inflammatory cytokines on the aorta endothelia are up-regulated in pinealectomized rats. Inflammation 2013, 36:1363-1373.
305. Wijnen H. Circadian rhythms. A circadian loop asSIRTs itself. Science 2009, 324:598-599.
306. Wu Y.H., Swaab D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007, 8:623-636.
307. Wu U.-I., Mai F.-D., Sheu J.-N., Chen L.-Y., Liu Y.-T., Huang H.-C., Chang H.-M. Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adults rats with acute Klebsiella pneumoniae meningitis. J. Pineal Res. 2011, 50:159-170.
308. Yan L., Liu S., Wang C., Wang F., Song Y., Yan N., Xi S., Liu Z., Sun G. JNK and NADPH oxidase involved in fluoride-induced oxidative stress in BV-2 microglia cells. Mediators Inflamm. 2013, 2013:895975.
309. Yin J., Liu Y.H., Xu Y.F., Zhang Y.J., Chen J.G., Shu B.H., Wang J.Z. Melatonin arrests peroxynitrite-induced tau hyperphosphorylation and the overactivation of protein kinases in rat brain. J. Pineal Res. 2006, 41:124-129.
310. Young A.R.J., Narita M. SASP reflects senescence. EMBO Rep. 2009, 10:228-230.
311. Zhang M., Cao L.H., Yang X.L. Melatonin modulates glycine currents of retinal ganglion cells in rat. Neuroreport 2007, 18:1675-1678.
312. Zhao W.J., Zhang M., Miao Y., Yang X.L., Wang Z. Melatonin potentiates glycine currents through a PLC/PKC signalling pathway in rat retinal ganglion cells. J. Physiol. 2010, 588:2605-2619.
313. Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013, 8:888-899.
314. 1-42. J. Pineal Res. 2008, 45:157-165.